Ahmad, Yousif
Demir, Ozan
Rajkumar, Christopher
Howard, James P
Shun-Shin, Matthew
Cook, Christopher
Petraco, Ricardo
Jabbour, Richard
Arnold, Ahran
Frame, Angela
Sutaria, Nilesh
Ariff, Ben
Kanaganayagam, Gajen
Francis, Darrel
Mayet, Jamil
Mikhail, Ghada
Malik, Iqbal
Sen, Sayan
Clinical trials referenced in this document:
Documents that mention this clinical trial
Antithrombotic therapy in patients undergoing transcatheter aortic valve implantation
https://doi.org/10.1136/heartjnl-2018-314313
Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement
https://doi.org/10.1136/bmjopen-2020-042587
Management strategies and future challenges for aortic valve disease
https://doi.org/10.1016/s0140-6736(16)00586-9
Optimal antiplatelet strategy after transcatheter aortic valve implantation: a meta-analysis
https://doi.org/10.1136/openhrt-2017-000748
Subclinical leaflet thrombosis after transcatheter aortic valve implantation
https://doi.org/10.1136/heartjnl-2017-311818
Funding for this research was provided by:
National Institute of Health Research